All patients were subjected to medical castration/ androgen deprivation therapy (ADT) with monthly 3.75 mg leuprorelin acetate intramuscular injection until castrate levels of testosterone (<50ng/dL) were achieved.
Alendronate has not been studied in carcinoma prostate patients treated with androgen deprivation therapy. It has largely been studied in postmenopausal women and found to be effective in this population.
The December 7, 2015, issue of the Journal of Clinical Oncology published the results of a case-control study that found the risk of Alzheimer's disease was significantly higher among men who were prescribed androgen deprivation therapy for prostate cancer compared to those who did not receive it.*
STANFORD, Calif., Safar 28, 1437, December 10, 2015, SPA -- Androgen deprivation therapy, or ADT, is one of the primary methods of treating prostate cancer because of the role testosterone plays in tumor growth.
Forgoing androgen deprivation therapy cuts rather than raises overall and cardiac mortality in certain patients with prostate cancer, depending on their comorbidities, according to a Research Letter to the Editor published online Sept.
For men with hormone-sensitive metastatic prostate cancer, combining standard androgen deprivation therapy with six cycles of docetaxel resulted in a significantly longer overall survival, compared with standard ADT alone, according to a study published online in the New England Journal of Medicine.